Why the study?
Does eplerenone improve blood pressure and organ damage compared to indapamide in hypertensive patients inadequately controlled on CCBs and ARBs?
Does eplerenone improve blood pressure and organ damage compared to indapamide in hypertensive patients inadequately controlled on CCBs and ARBs?
In patients with resistant hypertension on CCBs and ARBs, eplerenone and indapamide provide similar BP lowering, but eplerenone may offer additional benefits on arterial stiffness and oxidative stress.
Answers are grounded in this paper and cite their sources.
Similar BP reductions seen with eplerenone or indapamide; leaves open differential target-organ effects by salt intake in larger studies.
The aim of the present study was to compare the effects of the aldosterone blocker eplerenone and thiazide-like diuretic indapamide on blood pressure (BP) and target organs with reference to salt intake in hypertensive outpatients. Twenty hypertensive patients (nine women and 11 men, mean age 71 ± 13 years) with inadequate BP control despite taking calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs) were administered eplerenone (50 mg/day) or indapamide (1 mg/day) for 3 months each in a randomized crossover manner. Salt intake, BP and indices of organ damage were assessed at baseline and at the end of each treatment period. Eplerenone and indapamide were similarly effective in lowering office and home BPs. Both the treatments significantly reduced the estimated glomerular filtration rate (eGFR) and increased serum uric acid levels. The treatment with eplerenone significantly increased serum potassium levels, whereas the treatment with indapamide significantly decreased them. The treatment with eplerenone significantly decreased pulse wave velocity and urinary 8-hydroxydeoxyguanosine levels. These changes were not significantly affected by the treatment with indapamide. In conclusion, eplerenone and indapamide were similarly effective in lowering office and home BPs in hypertensive patients treated with CCBs and ARBs. Eplerenone may exert more favorable effects on arterial stiffness and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Ohta et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: